主动靶向纳米粒子治疗结直肠癌的研究进展
摘要
结直肠癌是一种常见的消化道恶性肿瘤,在中国结直肠癌发病率呈逐年增高的趋势,给家庭及社会带来极大的经济负担。随着纳米技术快速发展和对结直肠癌生物学研究不断深入,靶向纳米药物成为研究热点。本文介绍纳米载体以抗原、适配体、细胞表面受体为靶标,装载现已成熟的化疗药物组成主动靶向纳米颗粒治疗结直肠癌。本文旨在总结主动靶向纳米颗粒治疗结直肠癌的进展。在此基础上,对主动靶向纳米颗粒治疗结直肠癌的前景进行了展望。
引文
[1] Chen W,Zheng R,Zhang S,et al.Cancer incidence and mortality in China,2013[J].Cancer Lett,2017,401:63-71.
[2] Rama AR,Jimenez-Lopez J,Cabeza L,et al.Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer[J].Curr Drug Deliv,2016,13(6):830-838.
[3] Wicki A,Witzigmann D,Balasubramanian V,et al.Nanomedicine in cancer therapy:challenges,opportunities,and clinical applications[J].J Control Release,2015,200:138-157.
[4] Zalba S,Contreras AM,Haeri A,et al.Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer[J].J Control Release,2015,210:26-38.
[5] Liu Z,Qi L,Li Y,et al.VEGFR2 regulates endothelial differentiation of colon cancer cells[J].BMC Cancer,2017,17(1):593.
[6] Tacconi C,Correale C,Gandelli A,et al.Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion[J].Gastroenterology,2015,148(7):1438-1451.e8.
[7] Lee SY,Yang CY,Peng CL,et al.A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy[J].Biomaterials,2016,86:92-105.
[8] Xiang D,Zheng C,Zhou SF,et al.Superior Performance of Aptamer in Tumor Penetration over Antibody:Implication of Aptamer-Based Theranostics in Solid Tumors[J].Theranostics,2015,5(10):1083-1097.
[9] Alibolandi M,Taghdisi SM,Ramezani P,et al.Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo[J].Int J Pharm,2017,519(1-2):352-364.
[10] Cheng Y,Zhao G,Zhang S,et al.AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin[J].PLoS One,2016,11(12):e0167094.
[11] Morfoisse F,Tatin F,Hantelys F,et al.Nucleolin Promotes Heat Shock-Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis[J].Cancer Res,2016,76(15):4394-4405.
[12] Benedetti E,Antonosante A,d′Angelo M,et al.Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model[J].Oncotarget,2015,6(39):42091-42104.
[13] Mosafer J,Abnous K,Tafaghodi M,et al.In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy[J].Eur J Pharm Biopharm,2017,113:60-74.
[14] Mekuria SL,Debele TA,Chou HY,et al.IL-6 Antibody and RGD Peptide Conjugated Poly(amidoamine) Dendrimer for Targeted Drug Delivery of HeLa Cells[J].J Phys Chem B,2016,120(1):123-130.
[15] Kesari MV,Gaopande VL,Joshi AR,et al.Immunohistochemical study of MUC1,MUC2 and MUC5AC in colorectal carcinoma and review of literature[J].Indian J Gastroenterol,2015,34(1):63-67.
[16] Taghavi S,Ramezani M,Alibolandi M,et al.Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery[J].Cancer Lett,2017,400:1-8.
[17] Xie J,Dong H,Chen H,et al.Exploring cancer metastasis prevention strategy:interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial[J].J Nanobiotechnology,2015,13:9.
[18] Qi Y,Zhou F,Zhang L,et al.Construction of interference vector targeting Ep-CAM gene and its effects on colorectal cancer cell proliferation[J].Drug Des Devel Ther,2015,9:2647-2652.
[19] Xie X,Li F,Zhang H,et al.EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery[J].Eur J Pharm Sci,2016,83:28-35.
[20] Thao le Q,Byeon HJ,Lee C,et al.Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer[J].Pharm Res,2016,33(3):615-626.
[21] Tummala S,Kumar MN,Pindiprolu SK.Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles[J].Drug Deliv,2016,23(9):3505-3519.
[22] De Miguel D,Gallego-Lleyda A,Ayuso JM,et al.High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer[J].Cancer Lett,2016,383(2):250-260.
[23] Yang CY,Liu HW,Tsai YC,et al.Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer[J].Cancer Biol Ther,2015,16(11):1641-1650.
[24] Kuo CY,Liu TY,Chan TY,et al.Magnetically triggered nanovehicles for controlled drug release as a colorectal cancer therapy[J].Colloids Surf B Biointerfaces,2016,140:567-573.
[25] Scomparin A,Salmaso S,Eldar-Boock A,et al.A comparative study of folate receptor-targeted doxorubicin delivery systems:dosing regimens and therapeutic index[J].J Control Release,2015,208:106-120.
[26] El-Hammadi MM,Delgado AV,Melguizo C,et al.Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil[J].Int J Pharm,2017,516(1-2):61-70.
[27] Le VM,Wang JJ,Yuan M,et al.An investigation of antitumor efficiency of novel sustained and targeted 5-fluorouracil nanoparticles[J].Eur J Med Chem,2015,92:882-889.
[28] Patel K,Sundara Raj B,Chen Y,et al.Cytotoxicity of folic acid conjugated hollow silica nanoparticles toward Caco2 and 3T3 cells,with and without encapsulated DOX[J].Colloids Surf B Biointerfaces,2016,140:213-222.
[29] Wang Y,Li P,Chen L,et al.Targeted delivery of 5-fluorouracil to HT-29 cells using high efficient folic acid-conjugated nanoparticles[J].Drug Deliv,2015,22(2):191-198.
[30] Wang S,Cao M,Deng X,et al.Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy[J].Adv Healthc Mater,2015,4(2):281-290.
[31] Lin CW,Lu KY,Wang SY,et al.CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release[J].Acta Biomater,2016,35:280-292.
[32] Liu K,Wang ZQ,Wang SJ,et al.Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy:therapeutic efficacy evaluation[J].Int J Nanomedicine,2015,10:6445-6454.
[33] Ding D,Yao Y,Yang C,et al.Identification of mannose receptor and CD163 as novel biomarkers for colorectal cancer[J].Cancer Biomark,2018,21(3):689-700.
[34] Xiong M,Lei Q,You X,et al.Mannosylated liposomes improve therapeutic effects of paclitaxel in colon cancer models[J].J Microencapsul,2017,34(6):513-521.
[35] Yuan Y,Wen J,Tang J,et al.Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin[J].Int J Nanomedicine,2016,11:6229-6238.
[36] Liao F,He W,Jiang C,et al.A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C[J].Onco Targets Ther,2015,8:3135-3142.
[2] Rama AR,Jimenez-Lopez J,Cabeza L,et al.Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer[J].Curr Drug Deliv,2016,13(6):830-838.
[3] Wicki A,Witzigmann D,Balasubramanian V,et al.Nanomedicine in cancer therapy:challenges,opportunities,and clinical applications[J].J Control Release,2015,200:138-157.
[4] Zalba S,Contreras AM,Haeri A,et al.Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer[J].J Control Release,2015,210:26-38.
[5] Liu Z,Qi L,Li Y,et al.VEGFR2 regulates endothelial differentiation of colon cancer cells[J].BMC Cancer,2017,17(1):593.
[6] Tacconi C,Correale C,Gandelli A,et al.Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion[J].Gastroenterology,2015,148(7):1438-1451.e8.
[7] Lee SY,Yang CY,Peng CL,et al.A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy[J].Biomaterials,2016,86:92-105.
[8] Xiang D,Zheng C,Zhou SF,et al.Superior Performance of Aptamer in Tumor Penetration over Antibody:Implication of Aptamer-Based Theranostics in Solid Tumors[J].Theranostics,2015,5(10):1083-1097.
[9] Alibolandi M,Taghdisi SM,Ramezani P,et al.Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo[J].Int J Pharm,2017,519(1-2):352-364.
[10] Cheng Y,Zhao G,Zhang S,et al.AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin[J].PLoS One,2016,11(12):e0167094.
[11] Morfoisse F,Tatin F,Hantelys F,et al.Nucleolin Promotes Heat Shock-Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis[J].Cancer Res,2016,76(15):4394-4405.
[12] Benedetti E,Antonosante A,d′Angelo M,et al.Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model[J].Oncotarget,2015,6(39):42091-42104.
[13] Mosafer J,Abnous K,Tafaghodi M,et al.In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy[J].Eur J Pharm Biopharm,2017,113:60-74.
[14] Mekuria SL,Debele TA,Chou HY,et al.IL-6 Antibody and RGD Peptide Conjugated Poly(amidoamine) Dendrimer for Targeted Drug Delivery of HeLa Cells[J].J Phys Chem B,2016,120(1):123-130.
[15] Kesari MV,Gaopande VL,Joshi AR,et al.Immunohistochemical study of MUC1,MUC2 and MUC5AC in colorectal carcinoma and review of literature[J].Indian J Gastroenterol,2015,34(1):63-67.
[16] Taghavi S,Ramezani M,Alibolandi M,et al.Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery[J].Cancer Lett,2017,400:1-8.
[17] Xie J,Dong H,Chen H,et al.Exploring cancer metastasis prevention strategy:interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial[J].J Nanobiotechnology,2015,13:9.
[18] Qi Y,Zhou F,Zhang L,et al.Construction of interference vector targeting Ep-CAM gene and its effects on colorectal cancer cell proliferation[J].Drug Des Devel Ther,2015,9:2647-2652.
[19] Xie X,Li F,Zhang H,et al.EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery[J].Eur J Pharm Sci,2016,83:28-35.
[20] Thao le Q,Byeon HJ,Lee C,et al.Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer[J].Pharm Res,2016,33(3):615-626.
[21] Tummala S,Kumar MN,Pindiprolu SK.Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles[J].Drug Deliv,2016,23(9):3505-3519.
[22] De Miguel D,Gallego-Lleyda A,Ayuso JM,et al.High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer[J].Cancer Lett,2016,383(2):250-260.
[23] Yang CY,Liu HW,Tsai YC,et al.Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer[J].Cancer Biol Ther,2015,16(11):1641-1650.
[24] Kuo CY,Liu TY,Chan TY,et al.Magnetically triggered nanovehicles for controlled drug release as a colorectal cancer therapy[J].Colloids Surf B Biointerfaces,2016,140:567-573.
[25] Scomparin A,Salmaso S,Eldar-Boock A,et al.A comparative study of folate receptor-targeted doxorubicin delivery systems:dosing regimens and therapeutic index[J].J Control Release,2015,208:106-120.
[26] El-Hammadi MM,Delgado AV,Melguizo C,et al.Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil[J].Int J Pharm,2017,516(1-2):61-70.
[27] Le VM,Wang JJ,Yuan M,et al.An investigation of antitumor efficiency of novel sustained and targeted 5-fluorouracil nanoparticles[J].Eur J Med Chem,2015,92:882-889.
[28] Patel K,Sundara Raj B,Chen Y,et al.Cytotoxicity of folic acid conjugated hollow silica nanoparticles toward Caco2 and 3T3 cells,with and without encapsulated DOX[J].Colloids Surf B Biointerfaces,2016,140:213-222.
[29] Wang Y,Li P,Chen L,et al.Targeted delivery of 5-fluorouracil to HT-29 cells using high efficient folic acid-conjugated nanoparticles[J].Drug Deliv,2015,22(2):191-198.
[30] Wang S,Cao M,Deng X,et al.Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy[J].Adv Healthc Mater,2015,4(2):281-290.
[31] Lin CW,Lu KY,Wang SY,et al.CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release[J].Acta Biomater,2016,35:280-292.
[32] Liu K,Wang ZQ,Wang SJ,et al.Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy:therapeutic efficacy evaluation[J].Int J Nanomedicine,2015,10:6445-6454.
[33] Ding D,Yao Y,Yang C,et al.Identification of mannose receptor and CD163 as novel biomarkers for colorectal cancer[J].Cancer Biomark,2018,21(3):689-700.
[34] Xiong M,Lei Q,You X,et al.Mannosylated liposomes improve therapeutic effects of paclitaxel in colon cancer models[J].J Microencapsul,2017,34(6):513-521.
[35] Yuan Y,Wen J,Tang J,et al.Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin[J].Int J Nanomedicine,2016,11:6229-6238.
[36] Liao F,He W,Jiang C,et al.A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C[J].Onco Targets Ther,2015,8:3135-3142.